newsfilter
← Latest News
GlobeNewswire·

Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates

On track for DENALI Part 2a dose confirmation in 1H 2026DENALI Part 2 trial topline readout expected by year end 2026; potential to support accelerated approvalOn track to initiate the ASPENOVA Phase 3, randomized,